Cancer, obesity, and opioid abuse pose a combined threat to the well-being of the people in the United States, affecting over 70% and costing more than $250 billion per year in medical expenses. The unavailability of sensing technologies addressing the fundamental molecular changes related to disease initiation, progression, and therapeutic interventions is a critical roadblock for successfully combating these diseases/disorders. Recent clinical studies have shown that microRNA (miRNA) in circulating blood could use as a potential biomarker for combating these diseases/disorders because miRNA expression take place first in the biochemical cascade and therefore, miRNA could provide reliable and clinically important information that is superior and appear earlier than other biomarkers. Despite this progress, miRNAs have not yet been translated or utilized in the clinical diagnosis of any disease. This lack of progress is partially due to the differences among and limitations of various detection technologies, which produce inconsistent and inaccurate results. To address this issue, we have developed a low-cost and disposable device that can detect and quantify target miRNA levels. MiRNA detection is an integrated two-step process that used external electric fields to selectively concentrate fluorophore-labeled target miRNAs in nanoscale metallic hotspots within the device and enhance the fluorescence intensity via multiple metal-fluorophore interactions. This paper demonstrates how external electric fields could modulate the radiative decay rate of fluorophore molecules and subsequently enhance the fluorescence intensity.
|